Paul-Ehrlich-Institut

Go to:

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Ebola Vaccines

Ebola fever vaccines protect against infection with the ebola virus.

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Ervebo

Ebola Zaire-Impfstoff (rVSVΔG-ZEBOV-GP, lebend)

Zur aktiven Immunisierung von Personen ab 18 Jahren Jahren zum Schutz vor der Ebola-Viruskrankheit (EVD, Ebola Virus Disease), die durch das Zaire-Ebola-Virus verursacht wird.

Merck Sharp & Dohme B.V.

 Mono EU/1/19/1392 11.11.2019

EPAR: Ervebo

Wird derzeit in Deutschland nicht vermarktet

Mvabea

Ebola-Impfstoff (MVA-BN-Filo, rekombinant)

Verwendung ab dem ersten Lebensjahr / Use from 1 year of age onwards

Janssen-Cilag International NV, Belgien

 Mono EU/1/20/1445 01.07.2020

EPAR: Mvabea

Wird derzeit in Deutschland nicht vermarktet

Zabdeno

Ebola-Impfstoff (Ad26.ZEBOV-GP, rekombinant)

Verwendung ab dem ersten Lebensjahr / Use from 1 year of age onwards

Janssen-Cilag International NV, Belgien

 Mono EU/1/20/1444 01.07.2020

EPAR: Zabdeno

Wird derzeit in Deutschland nicht vermarktet

Disclaimer

The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.

The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.

As of: PEI announcement No. 534 in BAnz AT 29.10.2025 B5.

Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)

Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.

If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.

Updated: 29.10.2025